Intellia Therapeutics (NTLA)
(Real Time Quote from BATS)
$26.52 USD
+0.10 (0.38%)
Updated Jul 26, 2024 03:42 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NTLA 26.52 +0.10(0.38%)
Will NTLA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NTLA
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
Other News for NTLA
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
7 Biotech Stocks to Keep on Your Clinical Radar
3 Gene Editing Stocks That Could Grow Your Wealth
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition